Abstract-Mechanisms of formation and growth of intracranial aneurysms are poorly understood. To investigate the pathophysiology of intracranial aneurysms, an animal model of intracranial aneurysm yielding a high incidence of large aneurysm formation within a short incubation period is needed. We combined two well-known clinical factors associated with human intracranial aneurysms, hypertension and the degeneration of elastic lamina, to induce intracranial aneurysm formation in mice. Roles of matrix metalloproteinases (MMPs) in this model were investigated using doxycycline, a broad-spectrum MMP inhibitor, and MMP knockout mice. Hypertension was induced by continuous infusion of angiotensin II for 2 weeks. The disruption of elastic lamina was achieved by a single stereotaxic injection of elastase into the cerebrospinal fluid at the right basal cistern. A total of 77% of the mice that received 35 milliunits of elastase and 1000 ng/kg per minute of angiotensin II developed intracranial aneurysms in 2 weeks. There were dose-dependent effects of elastase and angiotensin II on the incidence of aneurysms. Histologically, intracranial aneurysms observed in this model closely resembled human intracranial aneurysms. Doxycycline, a broad-spectrum MMP inhibitor, reduced the incidence of aneurysm to 10%. MMP-9 knockout mice, but not MMP-2 knockout mice, had reduced the incidence of intracranial aneurysms. In summary, a stereotaxic injection of elastase into the basal cistern in hypertensive mice resulted in intracranial aneurysms that closely resembled human intracranial aneurysms. The intracranial aneurysm formation in this model appeared to depend on MMP activation. Key Words: intracranial aneurysm Ⅲ subarachnoid hemorrhage Ⅲ mice Ⅲ elastase Ⅲ models Ⅲ matrix metalloproteinase I ntracranial aneurysms are considered to be common among the general population. Subarachnoid hemorrhage from ruptured intracranial aneurysms results in catastrophic consequences causing severe morbidity and high mortality. 1 Despite recent advances in diagnosis and treatment, the mechanisms for the formation, growth, and subsequent rupture of intracranial aneurysms are not yet well understood.
I
ntracranial aneurysms are considered to be common among the general population. Subarachnoid hemorrhage from ruptured intracranial aneurysms results in catastrophic consequences causing severe morbidity and high mortality. 1 Despite recent advances in diagnosis and treatment, the mechanisms for the formation, growth, and subsequent rupture of intracranial aneurysms are not yet well understood.
Clinically, systemic hypertension is associated with intracranial aneurysm formation and subarachnoid hemorrhage from aneurysmal rupture. [2] [3] [4] However, a causal relationship between hypertension and intracranial aneurysm formation or subarachnoid hemorrhage has not been fully established. Histologically, degeneration and disruption of the elastic lamina are key characteristics of human intracranial aneurysm. 2, 5, 6 Degeneration or disruption of elastic lamina may be attributed to the normal aging process or damages caused by hemodynamic stresses. 7 Such changes in the elastic lamina have often been considered as preaneurysmal changes that eventually lead to the maturation of aneurysms. 8, 9 Elastaseinduced fragmentation of elastic lamina has been successfully used to induce aneurysms in the carotid artery 10, 11 and aorta 12 in animals. In these models, because of the ease of surgical or endovascular access of these blood vessels, elastase was applied intraluminally to induce degeneration of elastic lamina.
In this study, we present a new mouse model of intracranial aneurysms. To induce intracranial aneurysm formation, we combined hypertension and the degeneration of elastic lamina, two well-known clinical factors associated with human intracranial aneurysms. Hypertension was induced by continuous infusion of angiotensin II; degradation of elastic lamina was induced by a single injection of elastase into the cerebrospinal fluid using a stereotaxic method. Intracranial aneurysms in this model histologically mimic human intracranial aneurysms. In addition, roles of matrix metalloproteinases (MMPs) in this model were investigated using the MMP inhibition by doxycycline, a broad-spectrum MMP inhibitor, and MMP knockout mice.
To test whether the combination treatment of single elastase injection and pharmacologically induced hypertension can cause the formation of intracranial aneurysms in mice, we treated C57BL/6J mice (8 to 10 weeks old) with a single stereotaxic injection of elastase at the right basal cistern, immediately followed by induction of systemic hypertension with continuous injection of angiotensin II. After 2 weeks, we euthanized the mice and perfused the animals with a bromophenol blue dye and gelatin mixture.
Our preliminary study indicated a wide variation in vessel diameter for the Circle of Willis and its major branches in mice. To have a conservative and consistent control for our experiment, we used the diameter of the basilar artery, one of the larger vessels in the brain circulation with relatively little variation, as a reference blood vessel. Aneurysms were operationally defined as a localized outward bulging of the vascular wall of which the diameter is Ͼ150% of the basilar artery diameter. The Circle of Willis or its major primary branches were assessed by 2 investigators in a blinded manner.
To assess the relationship between the elastase dose and the incidence of aneurysms, 4 groups of mice were prepared: group 1 used 35.0 milliunits of heat-inactivated elastase; group 2 used PBS (nϭ10); group 3 used 3.5 milliunits of elastase (nϭ10); group 4 used 17.5 milliunits of elastase (nϭ20); and group 5 used 35 milliunits of elastase (nϭ44). Angiotensin II was administered at 1000 ng/kg per minute for 2 weeks in all of the groups.
To assess the relationship between the angiotensin II concentration and the incidence of aneurysms, 3 groups of mice were prepared: group 1 used continuous infusion of PBS via osmotic pump (nϭ10); group 2 used 500 ng/kg per minute of angiotensin II (nϭ10); and group 3 used 1000 ng/kg per minute of angiotensin II (nϭ44). This group (group 3) is the same as group 5 in the above-mentioned experiment testing the dose dependency of elastase effects. Thirtyfive milliunits of elastase were administered to all of the groups.
Doxycycline Treatment and MMP Knockout Mice
To assess the effects of doxycycline, a broad-spectrum MMP inhibitor, on the incidence of aneurysms, 10 mice received the doxycycline through drinking water (40 mg/kg per day). Doxycycline treatment was started 3 days before the elastase injection and continued for 17 days (3 daysϩ2 weeks). Previously, this dose administered through drinking water was used to successfully suppress MMPs involved in various disease models in mice. [13] [14] [15] For the control group, 10 mice received drinking water without doxycycline. These mice are different from the mice used in the doseresponse studies describe above. To assess of roles of MMP-9 and MMP-2 specifically, we used MMP-9 knockout mice and MMP-2 knockout mice (nϭ10 in each group). 16 All of the mice received a single injection of 35 milliunits of elastase and angiotensin II (1000 ng/kg per minute).
Statistical Methods
For continuous variables, we used ANOVA followed by Fisher least significant difference test, which was performed as a posthoc analysis. When repeated measurements were performed, ANOVA with a repeated measurement design was used. For the incidence, we used the 2 test. Data are presented as meanϮSD. Statistical significance was taken at PϽ0.05.
Results

Formation of Intracranial Aneurysm by a Combination of a Single Stereotaxic Injection of Elastase Into the Basal Cistern and Angiotensin II-Induced Hypertension
Among the mice that received a single stereotaxic injection of elastase at 35 milliunits into the basal cistern and a continuous SC infusion of angiotensin II at 1000 ng/kg per minute, 77% of the mice (34 of 44) were found to have developed intracranial aneurysm formations along the Circle of Willis or its major branches. Figure 1C through 1E) . To visualize the Circle of Willis and its major branches, mice were perfused with blue dye (bromophenol blue). In the mice treated with angiotensin II and elastase, large intracranial aneurysm formations were found mostly along the right half of the Circle of Willis and its major branches ( Figure 1C through 1E) . Most of the aneurysms were Ͼ500 m, Ϸ3 to 5 times larger than their parent arteries. A mouse that died at day 12 had fresh blood clots along the right middle cerebral artery ( Figure 1E ), revealing subarachnoid hemorrhage. There was a larger aneurysm formation inside the blood clots of subarachnoid hemorrhage ( Figure 1E ). Figure 1F shows the locations of intracranial aneurysms in mice that received a single stereotaxic injection of 35 milliunits of elastase and a continuous infusion of angiotensin II at 1000 ng/kg per minute. The majority of the intracranial aneurysms were located ipsilaterally to the elastase injection site. This was consistent with the bromophenol blue dye distribution found in the test dye injection. Small numbers of intracranial aneurysms were found on the contralateral side of the injection site, as well as on the branches of the basilar artery.
Continuous infusion of angiotensin II successfully induced systemic hypertension. At 1 week and 2 weeks after the initiation of continuous infusion of angiotensin II at 1000 ng/kg per minute, the blood pressure was significantly higher than the baseline (109Ϯ11 versus 142Ϯ37 versus 140Ϯ30 mm Hg; PϽ0.05; Figure 2C ).
To investigate the kinetics of elastase activity after a single injection of elastase into the cerebrospinal fluid space, we analyzed elastase activity in the cerebrospinal fluid after elastase injection. Elastase activity levels were under the detection levels (Ͻ0.005 U/mL) at the baseline or after sham injection. At 30 minutes or at 6 hours after the injection of 35 milliunits of elastase (nϭ3 in each group), elastase levels were under the detection level. As a next step, we injected 350 milliunits of elastase, a dose 10 times higher than what was actually used to induce aneurysms. At 30 minutes after injecting 350 milliunits of elastase, the elastase levels were 0.025Ϯ0.003 U/mL (nϭ3). At 6 hours after injecting 350 milliunits of elastase, the elastase activity levels returned to levels under the detection level (nϭ3). These data indicate that the elastase activity after a single injection of elastase was relatively short. Figure 2A shows a dose-dependent relationship between the incidence of intracranial aneurysm and the concentration of elastase. The incidence of aneurysms in groups that received 35 milliunits of heat-inactivated elastase, as well as 0.0 (PBS injection), 3.5, 17.0, and 35.0 milliunits of elastase, were 0%, 0%, 10%, 30%, and 77%, respectively. Figure 2B shows a dose-dependent relationship between the incidence of intracranial aneurysms and the concentration of angiotensin II. The total incidence of aneurysms in groups that received 0 (PBS infusion), 500, and 1000 ng/kg per minute of angiotensin II were 0%, 20%, and 77%, respectively. The blood pressures for groups that received 0 (PBS), 500, or 1000 ng/kg per minute of angiotensin II were 111.0Ϯ6.7, 127.0Ϯ18.8, and 142.0Ϯ37.0 mm Hg, respectively, at 1 week (PϽ0.05; Figure 2C ), showing a dosedependent effect of angiotensin II on the blood pressure.
Dose-Dependent Effects of Elastase and Angiotensin II on the Incidence of Intracranial Aneurysms
Histological Assessment of Intracranial Aneurysm Tissues
Histological assessment of intracranial aneurysm tissues from this model showed aneurysm formations with varying degrees of structural abnormalities that were similar to those reported in human intracranial aneurysms. 2 Generally, intracranial aneurysms in this model had a vascular wall with thick segments. Figure 3 shows a normal basilar artery ( Figure 3A and 3C) and a representative intracranial aneurysm ( Figure 3B and 3D ).
In the normal cerebral artery from control mouse ( Figure  3A and 3C), there were 2 to 3 layers of smooth muscle cells ( Figure 3A2 ) and a single, thin continuous layer of endothelial cells ( Figure 3A3 ). Fibroblasts were very scarce ( Figure   3A4 ). Elastica van Gieson and trichrome ( Figure 3C1 and 3C2) staining showed 1 layer of elastic lamina, as described previously. 2 In an intracranial aneurysm ( Figure 3B and 3D), the thin vascular wall showed intact endothelial and smooth muscle cell layers, whereas the thick vascular wall showed discontinued endothelial cell layers and scattered, faint smooth muscle staining ( Figure 3B2 and 3B3). Elastica van Gieson and trichrome stainings revealed severely disorganized elastic lamina in both thin and thick portions of the artery ( Figure 3D and 3E).
Potential roles of inflammation in the growth of intracranial aneurysms (both ruptured and unruptured) have been suggested by observational studies analyzing the presence of inflammatory cells or inflammatory markers in human intracranial aneurysm tissues and serum samples. 6, 7, 17, 18 Therefore, we investigated the presence of inflammatory cells in our intracranial aneurysm samples. Figure 4 shows a normal cerebral artery and a representative intracranial aneurysm.
A normal basilar artery from the control mouse ( Figure  4A ) showed an absence of inflammatory cells. In the intracranial aneurysm tissue ( Figure 4B ), leukocytes (CD45-positive cells) were present throughout the vascular wall Black arrows indicate intracranial aneurysm formations. Large intracranial aneurysm formations were found mostly along the right half of the Circle of Willis and its major branches. C, Intracranial aneurysm at the right posterior communicating artery. D, Intracranial aneurysm at the right middle cerebral artery. E, A mouse that died at day 12 had fresh blood clots along the right middle cerebral artery, revealing subarachnoid hemorrhage. Inside the blood clots of subarachnoid hemorrhage, there was a larger aneurysm formation. F, Locations of intracranial aneurysms found in the mice that received 35 milliunits of elastase and 1000 ng/kg per minute of angiotensin II (nϭ44). The majority of the intracranial aneurysms were located ipsilaterally to the elastase injection site. Small numbers of intracranial aneurysms were found on the contralateral side of the injection site, as well as on the branches of the basilar artery.
( Figure 4B1 ). Distribution of macrophages (CD68-positive cells) generally overlapped with the leukocyte distribution ( Figure 4B2 ). Small numbers of CD4-positive T lymphocytes were present in the thin-wall portion of the aneurysm. However, CD4-positive T lymphocytes were not detected in the thick aneurysm wall ( Figure 4B4 ).
Potential Roles of MMPs in the Formation of Intracranial Aneurysms
The presence of inflammatory cells in intracranial aneurysms tissues suggests potential roles of proteinases produced by inflammatory cells in the formation of intracranial aneurysms. 7, 17 Studies showed elevation of serum elastase and collagenase in patients with intracranial aneurysms, 19 -22 and MMP-9 and MMP-2 were detected in human intracranial aneurysm tissues. 23 To test potential contributions from MMPs to the formation of intracranial aneurysms in this model, 3 lines of experiments were performed. First, MMP activity in intracranial aneurysm tissues was assessed using in situ zymography. Second, we treated the mice with doxycycline, a broad-spectrum MMP inhibitor. Third, intracranial aneurysm formation was assessed in MMP-9 and MMP-2 knockout mice. Figure 5A through 5F shows in situ zymography and hematoxylin/eosin stainings of a normal brain vasculature and a representative intracranial aneurysm in this model.
Although the normal brain vasculature lacked any appreciable gelatinase activity ( Figure 5B ), intracranial aneurysms showed intense fluorescence, indicating robust gelatinase activity ( Figure 5A ). Pretreatment of the tissues with 1,10-phenanthroline monohydrate (MMP inhibitor) abolished the gelatinase activity ( Figure 5C) , showing that the gelatinase activity observed in the intracranial aneurysm tissues was from MMPs. Figure 5G shows the incidence of intracranial aneurysms in the control group (wild type), doxycycline-treated group (wild type), MMP-9 knockout mice, and MMP-2 knockout mice. All of the groups received the elastase injection and angiotensin II infusion. The incidence of intracranial aneurysms in the control group (wild type) was 70%, consistent with the results from the dose-dependence studies described above. The doxycycline treatment reduced the incidence of intracranial aneurysms to 10% (PϽ0.05), indicating potential roles for MMPs in the formation of aneurysms in this model. Similar results were reported previously using a different model of intracranial aneurysms in rats. 24 The incidence of intracranial aneurysms was reduced to 40% in MMP-9 knockout mice compared with the wild-type mice (PϽ0.05). However, there was no difference in the incidence of aneurysms between the wild-type mice and MMP-2 knockout mice (70% versus 60%). 
Discussion
In this study, we showed that the combination of hypertension and a single stereotaxic injection of elastase into the cerebrospinal fluid at the basal cistern resulted in the formation of intracranial aneurysms that recapitulated key features of human intracranial aneurysms. The single stereotaxic injection of elastase was used to induce disorganization or disruption of elastic lamina, a structural change that is considered to be preaneurysmal change. 10, 11, 25 To induce systemic hypertension, we used continuous infusion of angiotensin II via a subcutaneously implanted osmotic pump. This is a wellestablished and easily reproducible method of inducing hypertension in mice. 26, 27 Although neither systemic hypertension nor degeneration of elastic lamina alone could cause intracranial aneurysms in our model, the combination of both factors resulted in large aneurysm formation. These findings suggest the synergistic effects of these 2 factors in the formation of intracranial aneurysms in this model. In addition, we were able to show dose-dependent effects of angiotensin II and elastase on the formation of aneurysms, further supporting the causative roles of hypertension and degeneration of elastic lamina in aneurysm formation in this model. Aneurysms formed in this model were generally large and easily distinguishable from the normal arteries without using histological assessment. Aneurysm formation in this model can serve as a simple and easily interpretable outcome for future studies that use various inhibitors, knockout mice, or transgenic mice to test the roles of specific molecules and pathways in the pathophysiology of intracranial aneurysms.
Histologically, intracranial aneurysms observed in this model closely resembled human intracranial aneurysms. 2 The intracranial aneurysms in this model showed thin and thick vascular walls with partial loss of smooth muscle cells; elastic laminas showed various degenerative changes ranging from a partial disruption to a complete loss. In addition, the infiltration of leukocytes, especially macrophages, into the aneurysm wall was clearly present in our model, consistent with the observational studies that analyzed human intracranial aneurysm tissues and serum samples. 6, 17 In this model, intracranial aneurysms formed within 2 weeks. Such a short incubation time for this model's intracranial aneurysm formation would allow practical and feasible screening of various molecular targets. However, it should be cautioned that aneurysm formation and maturation are believed to require a much longer time frame in humans. The relatively shorter time span of aneurysm formation in this model may be attributable to the higher magnitude of physiological insults (hypertension and elastase-induced inflam- 
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mation) generated to create the model. In animal models, inciting factors that lead to the disease often need to be exaggerated or accentuated to achieve a severe disease phenotype at high incidence within a practical time frame.
However, by doing so, the model may fail to recapitulate or skip events that play key roles in the human disease. Although angiotensin II-induced hypertension is a wellestablished, well-characterized model of hypertension in mice, 26, 27 the effects of angiotensin II are diverse. Angiotensin II can exert various effects on the vasculature in addition to its hypertensive effect, including induction of reactive oxygen species and promotion of inflammation. 28 -30 Such nonhemodynamic effects of angiotensin II may have contributed to intracranial aneurysm formation in this model. In abdominal aortic aneurysms induced by angiotensin II in apolipoprotein E knockout mice, the nonhemodynamic effects appeared to be major causative factors. 31, 32 Additional studies are needed to elucidate relative contributions from nonhemodynamic effects and hypertensive effects of angiotensin II in this model.
The potential roles of proteinases, especially MMPs, in the formation of intracranial aneurysms have been suggested by observational, genetic, and experimental studies. 19 -23,33 In our study, we detected increased MMP activity in intracranial aneurysm tissues, and the treatment with doxycycline, a broad-spectrum MMP inhibitor, dramatically reduced the incidence of intracranial aneurysms. Interestingly, the incidence of aneurysms was significantly reduced in MMP-9 knockout mice but not in MMP-2 knockout mice. MMP-9 is known to be produced by inflammatory cells, especially macrophages, and its expression is upregulated in vascular diseases, including abdominal aortic aneurysms. 34, 35 On the other hand, MMP-2 is constitutively expressed by fibroblasts and smooth muscle cells in vascular tissues. Hemodynamic Figure 5 . Roles of MMPs in intracranial aneurysm formation. In situ zymography with or without an MMP inhibitor was performed on a normal cerebral artery (B) and a representative intracranial aneurysm in this model (A). Although the normal brain vasculature lacked any appreciable gelatinase activity (B), intracranial aneurysms showed intense fluorescence, indicating robust gelatinase activity (A). Pretreatment of the tissues with 1,10-phenanthroline monohydrate (MMP inhibitor) abolished the gelatinase activity (C), showing that the gelatinase activity observed in the intracranial aneurysm tissues was from MMPs. Incidence of intracranial aneurysms in 4 groups of mice is presented in G. The incidence of intracranial aneurysms in the control group (wild type) was 70%, consistent with the results from the dose-dependence studies described above. The doxycycline treatment reduced the incidence of intracranial aneurysms to 10% (PϽ0.05). The incidence of intracranial aneurysms was reduced to 40% in MMP-9 knockout mice compared with the wild-type mice (PϽ0.05). However, there were no differences in the incidences of aneurysms between the wild-type mice and MMP-2 knockout mice. KO indicates knockout mice. stress induced by systemic hypertension can trigger an inflammatory process by activating endothelial and inflammatory cells and upregulating leukocyte adhesion molecules. 36 In addition, the degeneration of elastic lamina by elastase in this model can trigger vascular inflammation. MMP-9 produced by inflammatory cells may destabilize the vascular wall and facilitate excessive vascular remodeling, causing aneurysm formation. The constitutive nature of MMP-2 expression may suggest that MMP-2 is not critical for dynamic vascular remodeling processes that may be occurring during aneurysm formation. Alternatively, unknown developmental compensation may have masked effects of the lack of MMP-2 on intracranial aneurysm formation in this model.
It should be noted that the greater reduction in the incidence of aneurysms in doxycycline-treated mice compared with MMP-9 knockout mice may suggest potential contributions from other MMPs to aneurysm formation in this model. In addition, doxycycline has other effects in addition to inhibiting MMPs, including the modulations of various aspects of inflammation. 37, 38 These additional effects of doxycycline may have diminished or masked its MMP-inhibitory effects. Nevertheless, these data showed the feasibility of using this model to study underlying mechanisms for intracranial aneurysm formation.
Hashimoto and colleagues 5, 25, 39, 40 at Kyoto University pioneered the development of an elaborate intracranial aneurysm model that combines 3 surgical and pharmacological manipulations. They combined the following 3 parts: (1) renovascular hypertension induced by ligation of posterior branches of the bilateral renal arteries and loading with a high-salt diet; (2) continuous administration of a lathyrogen, ␤-aminopropionitrile; and (3) unilateral ligation of a common carotid artery. Animals in this model developed preaneurysmal changes or microscopic intracranial aneurysm formations at the olfactory artery-anterior cerebral artery bifurcation after 3 to 4 months. Not only did their model and our model share the histological characteristics of aneurysms, but both models also showed that pharmacological inhibitions of MMPs result in the reduction of intracranial aneurysm formation. 24 Although the initial events that lead to aneurysm formation in these 2 model may be different, both models may be sharing common downstream pathways, including MMP activation, that lead to the same end phenotype: aneurysm formation.
Perspectives
We established a new mouse model of intracranial aneurysm that recapitulates key characteristics of human intracranial aneurysms. In this model, the combination of hypertension and the degeneration of elastic lamina induced by a single stereotaxic injection of elastase into the cerebrospinal fluid resulted in large aneurysm formations with the incidence as high as 77%. The aneurysm formation in this model appeared to depend on MMP activity. This model can be used to study molecular mechanisms that lead to aneurysm formation and growth. 
Mouse model of intracranial aneurysm
Intracranial aneurysms were induced by the combination treatment of single elastase injection and pharmacologically-induced hypertension in mice. To determine an adequate volume of elastase to inject for it to spread over the right half of Circle of Willis region, we stereotaxically injected various volumes of bromophenol blue dye solution dissolved in phosphate buffered saline (PBS) (2 mg/mL) into the right basal cistern. C57BL/6J mice (8-10 weeks old, Jackson Laboratory) were anesthetized with intraperitoneal injection of ketamine (100 mg/kg) and xylazine (10 mg/kg) (K-113, Sigma). To induce hypertension, an osmotic pump (Model 1002, Alzet pump, Durect Corp.) containing angiotensin-II (A9525, Sigma Aldrich) was implanted under the dorsal skin through 1 cm skin incision as previously described.
1, 2 Angiotensin II was dissolved in PBS, and administered at a dose of 500 or 1000 ng/kg/min. Then, the mouse was fixed in the stereotaxic frame with mouse adaptor (World Precision Instruments) (Supplemental Figure S1 ) to place the mouse skull horizontally. We stereotaxically placed the tip of the needle (10microL syringe Model 701 with 26g 2inch Hamilton Replacement needle Point style 3, Fisher Scientific) at the right basal cistern using the coordinate obtained from Mouse Brain Atlas (2.5 mm posterior to the bregma, 1.0 mm lateral to the midline, and 5.0 mm ventral to the skull surface). Elastase (E7885, porcine pancreatic elastase, lyophilized powder, 20mg, Sigma Aldrich) was dissolved in PBS. 2.5 µL of the elastase solution (0 -35 milli-units) was injected at 0.2 µL/min (Ultramicropump, World Precision Instruments). The entire procedure took approximately 30 minutes. To confirm the accuracy of the needle placement at the right basal cistern, we performed a dye injection using the same coordinates every 10 mice.
Systolic blood pressure was measured before the treatment (day 0) and one and two weeks after the elastase injection using the tail cuff method (ML125M, ADinstruments).
1
Tissue collection
Two weeks after the injection of elastase and the implantation of osmotic pump, mice were sacrificed and perfused with ice-cold saline followed by perfusion with a bromophenol blue dye solution (2mg/mL) dissolved in PBS and gelatin mixture (20%) at physiological pressure (approximately 80mmHg). The bromophenol blue dye and gelatin mixture was used to visualize major cerebral arteries. After taking macroscopic pictures of the major cerebral arteries, the brain tissues were fixed with 4% paraformaldehyde for 24 hours and then immersed in 15% sucrose for 24 hours and 30% sucrose for another 24 hours. Then, the tissues were frozen in OCT compound (Tissue-Tek) at -80˚C.
Serial cross-sections (10 µm thick) were mounted on microscope slides (Fisher Scientific Co.). Sections were stained with hematoxylin and eosin (H&E), Elastica van Gieson (EVG), and Gomori's trichrome histochemical examination. Other aortic cross-sections (10 µm thick) were prepared for immunohistochemical staining to identify pan-leukocytes, macrophages, helper 3 T-lymphocytes, B-lymphocytes, endothelial cells, fibroblasts, and smooth muscle cells. The following reagents were used to detect specific cell types: rat monoclonal anti mouse CD45 (1:1000 dilution; 553076) for pan-leukocytes, rat monoclonal anti mouse CD68 (1:300; MCA1957; AbD Serotec) for macrophages, rat monoclonal anti mouse CD4 (1:250; 553043) for helper T-lymphocytes, rat monoclonal anti mouse CD19 (1:100; 553783) for B-lymphocytes, rat monoclonal anti mouse CD31 (1:250; 553370) for endothelial cells, rabbit polyclonal anti S100A4 Ab-8 (1:150; RB-1804-A1; Neomarkers/Lab Vision) for fibroblasts, rabbit polyclonal anti alpha smooth muscle actin (1:400; AB5694; Abcam) for smooth muscle cells; these antibodies were purchased from BD Pharmingen, unless otherwise specified. The primary antibody was omitted for negative control. Sections were fixed with cold acetone for 20 minutes, and endogenous peroxidases were quenched by incubating sections in 0.3% hydrogen peroxide in methanol. Sections were subsequently blocked with 10% normal serum from host species of the secondary antibody. Sections were incubated in primary antibody overnight at 4°C, followed by incubation with corresponding biotinylated secondary antibodies (Vector Laboratories) and with a complex of avidin-biotinhorseradish peroxidase (Vector Laboratories). Immunoreactivity was visualized by incubating the sections with 0.05% 3,3'-diaminobenzidine (DAB, Vector Laboratories). Nuclei were visualized by counterstaining with aqueous hematoxylin.
In situ zymography
To detect gelatinase activity, specifically MMP activity, in intracranial aneurysm tissues, in situ zymography using gelatin as a substrate was performed as previously described. 3 To assess the contribution of MMP activity to the gelatinase activity, tissues were treated with MMP inhibitor (1,10-phenanthroline monohydrate, 500 µmol/L, 1hr).
